| Date | Time | Source | Headline | Symbol | Company |
| 03/04/2024 | 12:22PM | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/28/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/26/2024 | 5:28PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/26/2024 | 5:28PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/26/2024 | 5:26PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/26/2024 | 5:26PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/22/2024 | 8:50AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/22/2024 | 8:45AM | GlobeNewswire Inc. | Gracell Biotechnologies Acquisition Completed | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/20/2024 | 8:22AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/20/2024 | 7:45AM | GlobeNewswire Inc. | Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 02/14/2024 | 8:20AM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/30/2024 | 6:02AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/29/2024 | 7:00AM | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/17/2024 | 4:30PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/08/2024 | 4:01PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 01/08/2024 | 10:06AM | PR Newswire (US) | Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/26/2023 | 8:12AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/26/2023 | 6:44AM | Dow Jones News | Gracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZeneca | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/26/2023 | 3:05AM | Dow Jones News | AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/26/2023 | 2:01AM | Business Wire | AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/26/2023 | 2:00AM | GlobeNewswire Inc. | Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/22/2023 | 6:03AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/21/2023 | 7:00AM | GlobeNewswire Inc. | Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/18/2023 | 4:00PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 12/11/2023 | 7:30PM | GlobeNewswire Inc. | Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 11/29/2023 | 6:18AM | IH Market News | Amazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and More | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 11/28/2023 | 2:59PM | Dow Jones News | Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 11/27/2023 | 8:00AM | GlobeNewswire Inc. | Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 11/21/2023 | 6:25AM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GRCL | Gracell Biotechnologies Inc |
| 11/16/2023 | 8:00AM | GlobeNewswire Inc. | Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit | NASDAQ:GRCL | Gracell Biotechnologies Inc |